אייבו % 2 לילדים Ізраїль - іврит - Ministry of Health

אייבו % 2 לילדים

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 100 mg / 5 ml - ibuprofen

קובאלטרי IU 1000 Ізраїль - іврит - Ministry of Health

קובאלטרי iu 1000

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 1000 iu - coagulation factor viii

קובאלטרי IU 2000 Ізраїль - іврит - Ministry of Health

קובאלטרי iu 2000

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

קובאלטרי IU 250 Ізраїль - іврит - Ministry of Health

קובאלטרי iu 250

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii

קובאלטרי IU 500 Ізраїль - іврит - Ministry of Health

קובאלטרי iu 500

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

קימריה Ізраїль - іврит - Ministry of Health

קימריה

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

סנדאימון   ניאורל   50 מג כמוסות Ізраїль - іврит - Ministry of Health

סנדאימון ניאורל 50 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

סנדאימון   ניאורל   100 מג כמוסות Ізраїль - іврит - Ministry of Health

סנדאימון ניאורל 100 מג כמוסות

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

פרבליפ 10 Ізраїль - іврит - Ministry of Health

פרבליפ 10

unipharm ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 10 mg - pravastatin

בינוקריט 1000 יחבל 0.5 מל Ізраїль - іврит - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob